Soiken Holdings Inc. (2385) AI Stock Analysis

• Market Cap: ¥6.33B
• Dividend Yield: 2.08%
• Average Volume (3M): 187.76K
• Price to Earnings (P/E): 38.8
• Beta (1Y): 0.76
• Revenue Growth: -10.24%
• EPS Growth: N/A
• Country: JP
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.21
• Shares Outstanding: 26,158,200
• 10 Day Avg. Volume: 461,280
• 30 Day Avg. Volume: 187,763
• PEG Ratio: 0.31
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 0.91
• P/FCF Ratio: 8.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ¥270.00 ▲(14.41% Upside)

The score is held back primarily by deteriorated profitability and declining revenue despite a strong, debt-free balance sheet and improving (but still volatile) cash flow. Technicals are moderately supportive with price above key longer-term moving averages, while valuation is a notable drag due to a high P/E that is hard to support given the recent earnings weakness.

Positive Factors

Debt-free balance sheet

A zero-debt position materially reduces financial risk and preserves strategic optionality. Over the medium term this supports resilience through revenue volatility, lowers interest burden, and enables patient investment in R&D or M&A without near-term refinancing pressure, improving runway for execution.

Stable high gross margins

Consistently strong gross margins imply durable unit economics and pricing power in the company’s services/products. If top-line trends stabilize, these margins can support scalable operating leverage, fund research investment and recovery of operating profits, enhancing long-term profitability potential.

Return to positive operating & free cash flow in 2025

Re-establishing positive operating and free cash flow reduces near-term funding risk and signals improving working-capital or operational discipline. Durable cash generation, if sustained, increases internal funding for growth and R&D and lowers reliance on external capital over the next several quarters.

Negative Factors

Declining revenue trend

A multi-year top-line decline weakens scalability and puts pressure on fixed-cost absorption, R&D budgets and go-to-market effectiveness. Structural revenue erosion raises execution risk for recovering margins and makes long-term profit recovery and investment planning more challenging without clear demand stabilization.

Sustained net losses and falling returns

Consecutive annual net losses and weakened operating margins have turned returns negative, eroding capital efficiency. Persisting losses impair reinvestment capacity and investor confidence, and without a durable revenue turnaround, restoring acceptable returns on equity will remain difficult over the medium term.

Volatile cash generation history

Irregular historical cash flows increase execution risk: episodic negative years complicate budgeting and long-term R&D funding in biotech. Even with 2025 improvement, volatility limits confidence in sustaining investments, heightens sensitivity to adverse operating shocks, and can force reactive financing.

Soiken Holdings Inc. Business Overview & Revenue Model

Company Description

Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.

How the Company Makes Money

Soiken Holdings Inc. generates revenue through a multi-faceted business model centered around its healthcare and pharmaceutical services. The company earns income from the development and sale of health supplements and functional foods, which are distributed through various retail and online channels. Additionally, it provides healthcare consulting services, which contribute to its revenue streams. Partnerships with other healthcare companies and institutions play a significant role in expanding its market reach and enhancing its product offerings, thereby increasing its earnings potential.

Soiken Holdings Inc. Financial Statement Overview

Summary

Financials are mixed: profitability and revenue have weakened with net losses in 2024–2025 and declining revenue, but the balance sheet is strong with no debt and substantial equity. Cash flow improved in 2025 (positive operating cash flow/free cash flow) after volatility in prior years, reducing near-term funding risk but leaving execution risk around restoring sustainable profits.

Income Statement

Profitability has deteriorated materially: after solid operating and net profits in 2020–2023, the company swung to losses in 2024 and remained loss-making in 2025 (annual). While gross margin stayed relatively stable around the high-40% to ~50% range, operating margin turned negative and net margin was modestly negative in 2025 after a much larger loss in 2024—showing some improvement, but still below breakeven. Revenue is also trending down over the last three years (negative growth in 2023–2025), which raises concerns about near-term earnings recovery.

Balance Sheet

The balance sheet is conservatively positioned with no debt reported across all periods, which meaningfully reduces financial risk and provides flexibility. Equity remains substantial relative to assets, supporting overall stability. The main weakness is profitability-driven: returns on equity have turned negative in 2024–2025 after being healthy in 2020–2023, indicating the company is currently not generating acceptable returns on its capital base.

Cash Flow

Cash generation is mixed and somewhat volatile. The company produced strong positive operating cash flow and free cash flow in 2022, but cash flow was negative in 2021 and 2023 and fell sharply in 2024. Encouragingly, 2025 returned to positive operating cash flow and free cash flow, suggesting improving cash discipline or working-capital timing. However, the uneven pattern year-to-year limits confidence in the durability of cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.85B	4.85B	5.16B	8.08B	9.35B	8.94B
Gross Profit	2.41B	2.41B	2.48B	3.72B	4.26B	4.11B
EBITDA	-201.93M	-201.93M	-583.21M	750.07M	1.23B	948.13M
Net Income	-210.41M	-210.70M	-662.20M	451.85M	809.71M	562.06M
Balance Sheet
Total Assets	6.81B	6.81B	6.95B	8.24B	8.49B	7.15B
Cash, Cash Equivalents and Short-Term Investments	5.26B	5.26B	4.79B	5.95B	6.22B	4.26B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	775.16M	775.16M	697.02M	1.07B	1.64B	915.00M
Stockholders Equity	6.02B	6.02B	6.23B	6.97B	6.65B	6.04B
Cash Flow
Free Cash Flow	0.00	521.19M	-895.42M	-141.08M	2.09B	-131.65M
Operating Cash Flow	0.00	557.96M	-880.82M	-101.55M	2.14B	-107.44M
Investing Cash Flow	0.00	-389.41M	-14.29M	160.37M	-244.58M	-24.85M
Financing Cash Flow	0.00	-214.00K	-260.71M	-130.21M	-129.94M	-131.25M

Soiken Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 236.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Neutral. The current price of 236 is below the 20-day moving average (MA) of 248.55, below the 50-day MA of 245.52, and above the 200-day MA of 188.77, indicating a neutral trend. The MACD of 2.14 indicates Positive momentum. The RSI at 45.79 is Neutral, neither overbought nor oversold. The STOCH value of 3.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2385.

Soiken Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥14.31B	44.82	―	―	12.91%	37.96%
2385	58 Neutral	¥6.33B	38.76	―	2.08%	-10.24%	―
2342	56 Neutral	¥5.25B	-5.90	―	―	-0.77%	-288.43%
4594	53 Neutral	¥8.40B	-5.54	―	―	1221.43%	30.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4881	50 Neutral	¥3.53B	-1.97	―	―	-16.23%	-51.84%
4591	43 Neutral	¥4.56B	-3.54	―	―	-100.00%	7.60%